Evidence map›Paper›PMID 29337116›Full record

ArticleStem cell reports2018

Impact of Swiprosin-1/Efhd2 on Adult Hippocampal Neurogenesis.

Martin Regensburger, Iryna Prots, Dorothea Reimer, Sebastian Brachs, Sandra Loskarn, Dieter Chichung Lie, Dirk Mielenz, Beate Winner

Open access · goldAbstract read
In one paragraph

Article in Stem cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Martin RegensburgerDepartment of Stem Cell Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Glueckstrasse 6, Erlangen 91054, Germany; Department of Neurology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen 91054, Germany; IZKF Junior Research Group III and BMBF Research Group Neuroscience, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen 91054, Germany.
Iryna ProtsDepartment of Stem Cell Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Glueckstrasse 6, Erlangen 91054, Germany; IZKF Junior Research Group III and BMBF Research Group Neuroscience, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen 91054, Germany.
Dorothea ReimerDepartment of Molecular Immunology, Department of Internal Medicine III, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Glueckstrasse 6, Erlangen 91054, Germany.
Sebastian BrachsDepartment of Molecular Immunology, Department of Internal Medicine III, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Glueckstrasse 6, Erlangen 91054, Germany.
Sandra LoskarnDepartment of Stem Cell Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Glueckstrasse 6, Erlangen 91054, Germany; Department of Neurology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen 91054, Germany; IZKF Junior Research Group III and BMBF Research Group Neuroscience, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen 91054, Germany.
Dieter Chichung LieEmil-Fischer Centre, Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen 91054, Germany.
Dirk MielenzDepartment of Molecular Immunology, Department of Internal Medicine III, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Glueckstrasse 6, Erlangen 91054, Germany. Electronic address: dirk.mielenz@fau.de.
Beate WinnerDepartment of Stem Cell Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Glueckstrasse 6, Erlangen 91054, Germany; IZKF Junior Research Group III and BMBF Research Group Neuroscience, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen 91054, Germany. Electronic address: beate.winner@fau.de.
Friedrich-Alexander-Universität Erlangen-Nürnberg · DE

Funding

KOMP2-Phase3 Production and Phenotyping by the DTCC Consortium TCP Transfer to UC DavisUM1OD023221 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KC KENT LLOYD · 2016 to 2026
$45.7M
High-throughput targeted mutagenesis of mouse stem cell linesU01HG004080 · NHGRI · CHILDREN'S HOSPITAL & RES CTR AT OAKLAND · PI DE JONG, PIETER J. · 2006 to 2010
$28.1M
Production of Targeted Null Mutations for 10,000 Genes in C57BL/6 ES CellsU01HG004085 · NHGRI · REGENERON PHARMACEUTICALS, INC. · PI VALENZUELA, DAVID MANUEL · 2006 to 2010
$25.3M
UCD KOMP PROJECT REPOSITORYU42RR024244 · NCRR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LLOYD, KC KENT · 2007 to 2010
$7.9M
NCRR NIH HHS U42 RR024244NHGRI NIH HHS U01 HG004080NHGRI NIH HHS U01 HG004085NIH HHS UM1 OD023221
6 · The paper itself

Abstract

Swiprosin-1/Efhd2 (Efhd2) is highly expressed in the CNS during development and in the adult. EFHD2 is regulated by Ca

Indexed as

ActinsAlzheimer DiseaseAnimalsCalciumCalcium-Binding ProteinsCentral Nervous SystemGene Expression Regulation, DevelopmentalHippocampusHumansMiceMice, KnockoutNeuritesNeurogenesisNeuronal PlasticityNeuronsSpineActinsCalciumCalcium-Binding ProteinsEFHD2 protein, mouseadult neurogenesisdendritic spinesdoublecortinEfhd2Swiprosin-1TAU

Identifiers

PMID29337116
PMCPMC5830914
OpenAlexW2784287352

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.